On October 20, 2023, the board of directors of Quince Therapeutics, Inc. appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition. Mr. Benatti was designated as a Class II director whose term expires at the Company?s 2024 Annual Meeting of Stockholders.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.92 USD | +1.10% | -6.15% | -14.19% |
04-01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-26 | Transcript : Quince Therapeutics, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
-14.19% | 39.33M | |
+25.36% | 46.71B | |
+48.83% | 41.8B | |
-1.10% | 41.52B | |
-3.42% | 29.55B | |
+10.41% | 25.78B | |
-20.58% | 19.26B | |
+0.48% | 12.14B | |
-0.65% | 12.08B | |
+26.45% | 11.98B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Appoints Luca Benatti as Director